Trial Profile
Additional effect of statin to PegIFN/Ribavirin treatment in chronic hepatitis C patients
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 17 Oct 2016
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C; Hypercholesterolaemia
- Focus Therapeutic Use
- 17 Oct 2016 New trial record